Filer	Title/Relationship	Filing Date	Planned Shares	Est. Value
INGRID DELAET	Officer	2026-07-10	4K shares	$788K
DARIN LIPPOLDT	Officer	2026-07-09	10K shares	$1.78M
INGRID DELAET	Officer	2026-07-07	15K shares	$2.54M
Lippoldt Darin	Officer	2026-06-29	10K shares	$1.65M
Lippoldt Darin	Officer	2026-06-26	200 shares	$33K
SHERWIN STEPHEN A	Director	2026-06-05	25K shares	$4.18M

Form 144 is a planned sale notice, not an executed transaction. Form 144 Tracker。

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding NEUROCRINE BIOSCIENCES INC (NBIX)?

Major stakeholders currently include BlackRock, Inc. ($1.8B), Dodge & Cox ($719.4M), Jpmorgan Chase & Co ($700.5M). Based on the latest 13F filings, there are a total of 689 tracked investment funds and institutions maintaining positions in NBIX.

What is the overall institutional sentiment toward NBIX recently?

Institutional sentiment appears Bearish (Net Selling). During the most recent reporting quarter, the stock experienced a net outflow of $956.8M, driven by 369 managers accumulating shares while 327 reduced their exposure.

Which institutions have been selling or reducing their NBIX positions?

In the latest period, 217 funds trimmed their holdings, and 110 managers completely exited their positions. The aggregate reported sell value was $5.0B.

Are there any notable investors adding NBIX to their portfolios?

Yes, buying activity remains notable. 70 institutions opened new positions in {ticker}, and 299 existing holders added to their shares. The total reported buy value for the quarter amounted to $8.7B.